Drug discovery is undergoing a transformational change. Early-stage target identification, lead generation and optimization work is now undertaken in a much more diverse set of organizations, involving biotechnology companies and academia as well as large pharmaceutical companies.
Encouragingly, more and more pro jects are now also being conducted as genuine collaborations and not in isolation, as has traditionally been the case. All of this work benefits from access to information and data. Examples include the identification of tool compounds for a target, searching for novel templates and scaffolds or trying to understand and predict selectivity or absorption, distribution, metabolism, excretion and toxicity properties. Large pharmaceutical companies have often been able to make use of their extensive internal databases for such studies, but in today's world they and their counterparts in biotechnology and academia rely upon information in the public domain, such as publicly available databases and the scientific and patent literature.
In order to facilitate the overall efforts in drug discovery, and particularly to avoid 'rediscovering the wheel', we need to make it easier for scientists to share data and to make those data more readily available to the community via public databases.
There are a number of instances where this is already happening. For example, in the USA the funding agencies require data from publicly funded research under the Molecular Libraries Program to be deposited in a public database such as PubChem [1] . More recently data from neglected disease research [2] [3] have been deposited in the ChEMBL database [4] . This is, however, only a relatively recent development.
Can chemistry learn from the experience of other disciplines? The importance of publicly available data for research in the biology and bioinformatics fields is evident by the long-term funding and support that is in place for institutes such as the National Center of Biotechnology Information in the USA, and the European Bioinformatics Institute in Europe.
The worldwide PDB, the public database that contains 3D protein structures, was 40 years old last year [5] . Originally, coordinates were published in journal articles, and there was substantial space and cost implications for publishers associated with typesetting and distribution of the data. Of course, the data were unusable to all but the most persistent users, and it was obvious that a computer-based distribution media was required. In the years following the establishment of the PDB it became increasingly accepted by the structural biology community that structures should be deposited in a public database prior to publication. By 1989 the community under the International Union of Crystallography published a policy that effectively required the deposition of crystal structures at the time of publication [6] .
Protein structures are not unique in this respect. Most biological journals also insist that protein and nucleotide sequences must be deposited in GenBank or EMBL databases and genomic and proteomic data must be deposited in GEO before publication.
How can the chemistry community emulate this behavior? A critical step for protein structures was the availability of a database to hold the data. We now have publicly available bioactivity databases such as PubChem BioAssay and ChEMBL that are able to take data depositions. These databases also have data sharing agreements in place that regularly refresh the novel data in either database to present a unified, integrated whole. What can we do as a chemistry community to contribute to these resources?
Open data for drug discovery: learning from the biological community In databases such as ChEMBL, data are manually extracted from the chemical literature. Inevitably, the process of extracting numeric data and in particular chemical structures introduces errors. Scientists reporting their work in the literature will invariably already have chemical structures and bioactivity data stored in some common electronic format. The logical extension, therefore, is to deposit the chemical structures (e.g., as InChIs [7] ) alongside the bioactivity data into a public database at the same time as publication, just as it is for biological data. This would enable the community to find bioactivity data more easily, would reduce the propagation of errors and improve the quality of information in drug-discovery databases. Adoption of such an approach would also create stronger links between the detailed information present in the published literature and the broader drug-discovery context that the databases provide.
There may be other steps we could take. A typical peer-reviewed publication containing SAR data will often just include the data that support the key findings. There may be related data that are not included in the article but which could be made available to the wider community. There may, for example, be sets of inactive analogues, or SAR points that did not merit inclusion in the publication. Additional data might also become available after the original findings have been published but which may not merit a separate publication. Making these additional data (which we refer to as 'supplementary bioactivity data') available to the community could potentially be of great benefit for future drug-discovery projects. In our view the preferred way of making supplementary bioactivity data available is by directly submitting it to publicly available databases.
To test this concept we have compiled a set of supplementary bioactivity data and developed a simple process that allows for the data to be deposited in the ChEMBL database. This work was carried out as part of the Innovative Medicines Initiative [101] Open PHACTS project [8, 102] . GlaxoSmithKline selected a set of 54 compounds with associated bioactivity data that had not yet been disclosed. These were approved for public release using the standard GSK procedures. The compounds in the set are from a chemical series that was described in a recent publication [9] . Moreover, the data from the original publication already exist in the ChEMBL database. These new compounds thus provide additional SAR. Also the supplementary bioactivity data can easily be identified as data supplemental to the original publication.
If more groups follow this example of making data available to the community it will improve, not only the quantity, but also the quality, of data in databases that can be used for drug discovery. We should be clear that each group or organization will still need to develop and apply its own procedures for deciding what and when to publish. It is essential to ensure that there are then no practical impediments to making that data as widely available as possible. Funding agencies and governments are clearly moving in the direction of open access to the results (including the data) of research that they support [103] [104] [105] . A process for submitting data to ChEMBL is in place, so let's start now. No writing assistance was utilized in the production of this manuscript.
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